相关实验视频

Updated: Jan 13, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

异常多中心卡斯特曼病-TAFRO:一种潜在的可治愈疾病?

Lu Zhang^1,2, Jia-Ying Ge³, Si-Yuan Li^1,2

¹Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

American journal of hematology

|January 10, 2026

概括

异常多中心卡斯特曼病 (iMCD) -TAFRO患者达到完全缓解可能能够停止治疗. 一项研究发现,85.2%的患者维持了缓解,这表明在一些iMCD-TAFRO病例中,长期康复的可能性很大.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

异常多中心卡斯特曼病 (iMCD) -TAFRO是一种严重的iMCD亚型,以细胞因子风暴为特征,通常需要无限期治疗.
目前的理解表明,iMCD-TAFRO是无法治愈的,需要持续治疗,尽管关于终止治疗的长期数据有限.

研究的目的:

评估iMCD-TAFRO患者中断治疗的可行性和结果,这些患者实现了生物化学完全响应 (CR).
为了确定与iMCD-TAFRO中断治疗后持续缓解和疾病进展相关的因素.

主要方法:

对27名iMCD-TAFRO患者的回顾性分析,这些患者在实现生化CR后停止治疗.
收集的数据包括治疗史,进展时间和随访时间 (中位数为31个月).

主要成果:

85.2%的患者在停止治疗后保持生物化学CR,只有14.8%的患者出现疾病进展 (PD).
与维持缓解的患者相比,进展的患者在治疗前的CRP水平明显较低 (p=0.018).
3年后无进展生存率 (PFS) 为85.2%,所有患者仍然活着.

结论:

停止治疗可能是实现生化CR的iMCD-TAFRO患者的一个子集的可行选择.
较低的预治疗CRP可能预测在停止治疗后进展的风险更高.
对个性化治疗策略进行进一步的研究,包括停止治疗,对于iMCD-TAFRO管理是有必要的.

关键词:

可治愈的疾病可治愈的疾病.停止使用药物停止使用药物在 iMCD-TAFRO 中.异常多中心的卡斯特曼病.长期缓解缓解的方法

更多相关视频

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...